Abstract

The Sementis Copenhagen Vector (SCV) is a new vaccinia virus-derived, multiplication-defective, vaccine technology assessed herein in non-human primates. Indian rhesus macaques (Macaca mulatta) were vaccinated with a multi-pathogen recombinant SCV vaccine encoding the structural polyproteins of both Zika virus (ZIKV) and chikungunya virus (CHIKV). After one vaccination, neutralising antibody responses to ZIKV and four strains of CHIKV, representative of distinct viral genotypes, were generated. A second vaccination resulted in significant boosting of neutralising antibody responses to ZIKV and CHIKV. Following challenge with ZIKV, SCV-ZIKA/CHIK-vaccinated animals showed significant reductions in viremias compared with animals that had received a control SCV vaccine. Two SCV vaccinations also generated neutralising and IgG ELISA antibody responses to vaccinia virus. These results demonstrate effective induction of immunity in non-human primates by a recombinant SCV vaccine and illustrates the utility of SCV as a multi-disease vaccine platform capable of delivering multiple large immunogens.

Details

Title
The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates
Author
Prow, Natalie A 1 ; Liu, Liang 2 ; McCarthy, Mary K 3 ; Walters, Kevin 4 ; Kalkeri Raj 4 ; Geiger, Jillian 4 ; Koide Fusataka 4 ; Cooper, Tamara H 2 ; Eldi Preethi 2 ; Nakayama Eri 5   VIAFID ORCID Logo  ; Diener, Kerrilyn R 6 ; Howley, Paul M 7 ; Hayball, John D 2 ; Morrison, Thomas E 3 ; Suhrbier, Andreas 8 

1  QIMR Berghofer Medical Research Institute, Inflammation Biology, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395); Australian Infectious Disease Research Centre, Brisbane, Australia (GRID:grid.1049.c); University of South Australia, Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, UniSA Cancer Research Institute, Adelaide, Australia (GRID:grid.1026.5) (ISNI:0000 0000 8994 5086) 
2  University of South Australia, Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, UniSA Cancer Research Institute, Adelaide, Australia (GRID:grid.1026.5) (ISNI:0000 0000 8994 5086) 
3  University of Colorado School of Medicine, Department of Immunology and Microbiology, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X) 
4  Southern Research Institute, Department of Infectious Disease Research, Frederick, USA (GRID:grid.454225.0) (ISNI:0000 0004 0376 8349) 
5  QIMR Berghofer Medical Research Institute, Inflammation Biology, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395); National Institute of Infectious Diseases, Department of Virology I, Tokyo, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880) 
6  University of South Australia, Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, UniSA Cancer Research Institute, Adelaide, Australia (GRID:grid.1026.5) (ISNI:0000 0000 8994 5086); University of Adelaide, Robinson Research Institute and Adelaide Medical School, Adelaide, Australia (GRID:grid.1010.0) (ISNI:0000 0004 1936 7304) 
7  Sementis Ltd, Berwick, Australia (GRID:grid.1010.0) 
8  QIMR Berghofer Medical Research Institute, Inflammation Biology, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395); Australian Infectious Disease Research Centre, Brisbane, Australia (GRID:grid.1049.c) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20590105
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41541-020-0191-8
ProQuest document ID
2488772813
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.